Floatz logo

PE 2I

Dementia With Lewy Bodies (DLB)

Universitaire Ziekenhuizen KU LeuvenSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

36 Active assets in the Dementia With Lewy Bodies (DLB) cohort.

Asset / SponsorPhaseRating
Namenda
Zealand University Hospital
Phase 4BBB
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)
Virginia Commonwealth University
Phase 4BB
Armodafinil
NYU Langone Health
Phase 4BB
Sitagliptin
Mayo Clinic
Phase 4BB
Dapagliflozin
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

PE 2I is also rated in:

REM sleep behavior disorderDormant
CCC
Indicative ·
52 / 100
View asset →
Parkinson diseaseDormant
CC
Indicative ·
44 / 100
View asset →
Alzheimer diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →